CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer...
Phase 2
Fairfax, Virginia, United States and 46 other locations
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung ca...
Phase 2
Chevy Chase, Maryland, United States and 83 other locations
chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osim ...
Phase 2
Baltimore, Maryland, United States and 15 other locations
This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell lung cancer...
Phase 2
Fairfax, Virginia, United States and 49 other locations
a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...
Phase 2
Baltimore, Maryland, United States and 43 other locations
with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....
Phase 3
Bethesda, Maryland, United States and 209 other locations
This phase II clinical trial will study the safety and efficacy of onvansertib to treat patients with small cell lung cancer (SCLC)...
Phase 2
Baltimore, Maryland, United States and 1 other location
with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung ...
Phase 3
Columbia, Maryland, United States and 200 other locations
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...
Phase 2
Baltimore, Maryland, United States and 123 other locations
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...
Phase 2
Fairfax, Virginia, United States and 29 other locations
Clinical trials
Research sites
Resources
Legal